Fig. 4: Combination of molnupiravir and Brequinar reduces SARS-CoV-2 infection and inflammation in vivo.
From: Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
Wild-type BALB/C mice were treated with Brequinar (intraperitoneal administration) and/or molnupiravir (oral administration) daily at the indicated concentrations starting 12 h before infection. Mice (n = 5 per group over 2 independent experiments) were intranasally inoculated with 1 × 105 p.f.u. per mouse of SARS-CoV-2 (B.1.351). a–f, Lungs were analysed for viral titre 2 days after infection by plaque assay (a, d) or fixed in 4% paraformaldehyde for haematoxylin and eosin staining and quantified for interstitial inflammation (b, c, e, f). n = 5 mice per group. Mean ± s.d. is shown. *P < 0.05, **P < 0.01 and ***P < 0.001, using non-parametric one-way ANOVA with Dunnett’s multiple comparison test. The red asterisks are compared to vehicle; the blue asterisks are compared to molnupiravir. P values are listed in Extended Data Fig. 8d. Scale bars, 200 μM.
